Related Experiment Videos
[Dobutamine in childhood]
Insights
Dobutamine, a synthetic catecholamine, effectively manages low cardiac output in adults and children over 12 months. Close monitoring is crucial for neonates and infants due to potential growth-related cardiovascular changes affecting response.
Area of Science:
- Pharmacology
- Pediatric Cardiology
- Critical Care Medicine
Context:
- Dobutamine is a synthetic catecholamine with significant inotropic effects.
- It is commonly used in adult patients experiencing low cardiac output and elevated left ventricular end-diastolic pressure.
- Limited data exists on its pediatric hemodynamic effects, particularly in younger age groups.
Purpose:
- To review the hemodynamic effects of Dobutamine in pediatric patients.
- To assess its efficacy in treating acute low cardiac output states in children.
- To highlight the importance of monitoring in neonates and infants due to developmental cardiovascular changes.
Summary:
- Dobutamine demonstrates effectiveness in treating acute low cardiac output states in children older than 12 months.
- Neonates and infants also appear to respond to Dobutamine.
- However, growth-related cardiovascular alterations necessitate meticulous hemodynamic monitoring in these younger patients.
Impact:
- Provides insights into Dobutamine's use in pediatric critical care.
- Emphasizes the need for individualized treatment and close monitoring in specific pediatric populations.
- Contributes to understanding drug efficacy and safety across different age groups in pediatric cardiology.
Abstract:
The synthetic catecholamine Dobutamine has potent inotropic effects. It is frequently used in the management of adult patients with low cardiac output and elevated left ventricular enddiastolic pressure not yet associated with systemic hypotension. The few available informations on hemodynamic effects of Dobutamine in children emphasize the effectiveness of this sympathomimetic amine also in the treatment of children especially older than 12 months with acute low cardiac output states. Neonates and infants appear to respond to Dobutamine as well, but possible changes in cardiovascular structure and function accompanying growth which are discussed and which could cause a considerable variance in individual patient response, require an exceptionally close monitoring of the hemodynamic effects of Dobutamine in this age-group.